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Abstract: 
Purpose: In mechanically ventilated patients, the endotracheal tube is an 
essential interface between the patient and ventilator, but inadvertently it also 
facilitates the development of ventilator-associated pneumonia (VAP) by 
subverting pulmonary host defense. A number of investigations suggest that 
bacteria colonising the oral cavity may be important in the aetiology of VAP. 
The present study evaluated microbial changes that occurred in dental plaque 
and lower airways of 107 critically ill mechanically ventilated patients. 
Materials and Methods: Dental plaque and lower airways fluid was collected 
during the course of mechanical ventilation, with additional samples of dental 
plaque obtained during the entirety of patients’ hospital stay. Results: A 
‘microbial shift’ occurred in dental plaque, with colonisation by potential VAP 
pathogens, namely, Staphylococcus aureus and Pseudomonas aeruginosa in 
35 patients. Post-extubation analyses revealed that 70% and 55% of patients 
whose dental plaque included S. aureus and P. aeruginosa, respectively, 
reverted back to having a predominantly normal oral microbiota. Respiratory 
pathogens were also isolates from the lower airways and within the 
endotracheal tube biofilms. Conclusions: To the best of our knowledge, this 
is the largest study to date exploring oral microbial changes during both 
mechanical ventilation and following recovery from critical illness. Based on 
these findings, it was apparent that during mechanical ventilation, dental 
plaque represents a source of potential VAP pathogens.  
Introduction  
In mechanically ventilated patients the endotracheal tube is an essential 
interface between the lungs and the ventilator. Unfortunately, the presence of 
an endotracheal tube also impairs pulmonary host defenses and promotes 
ventilator-associated pneumonia (VAP) through supporting biofilm formation 
within its inner lumen [1,2]. In addition, the endotracheal tube and incomplete 
mouth closing will alter the oral microenvironment. VAP is the most common 
nosocomial infection in critical care with a prevalence of approximately 15% 
and prognosis is negatively influenced with involvement of multidrug resistant 
pathogen biofilms [3,4]. The endotracheal tube biofilm may serve as a 
reservoir of respiratory pathogens that are largely protected from host defense 
mechanisms. In recent years, studies into the origin of VAP causing 
microorganisms have primarily focused on oropharyngeal sites rather than the 
gastro-intestinal tract [5-8]. As a consequence, a number of recent strategies 
aimed at preventing VAP have sought to target the oral microbiome [9,10]. 
Dental plaque was initially considered to be a bacterial construct (i.e. a 
biofilm) in the 1970s [11]. Dental plaque harbors an estimated 500 different 
bacterial species with variation in microbial composition occurring between 
and along the teeth [12]. Streptococcus species are recognised as primary 
pioneer colonisers of teeth and are initiators of dental plaque development 
[13]. Lazarevic et al.  analysed the oral microbiome using molecular methods 
and reported that up to 70% of sequences belonged to the Streptococcus and 
Neisseria genera [14]. Saliva plays an important role in modulating dental 
plaque formation [15, 16]. Glycoproteins and proline-rich proteins (PRPs) in 
saliva will adsorb to tooth surfaces generating an enamel pellicle allowing 
bacteria to adhere [17]. 
 
The oral microbiome could promote VAP in several ways [18]. Firstly, during 
mechanical ventilation rapid colonisation by potential respiratory pathogens 
including Pseudomonas, Klebsiella, Staphylococcus aureus and 
Acinetobacter can occur and these bacteria may subsequently disseminate to 
the lung [8,19,20]. Secondly, commensal oral bacteria may actively promote 
respiratory pathogen colonisation of the endotracheal lumen, and these 
bacteria may again translocate to the lower airways leading to VAP [1,21]. 
Biofilm-mediated infections are difficult to treat, as not only are the cells 
protected within the biofilm structure, but the microorganisms involved are 
also frequently inherently less susceptible to antimicrobial agents [22-24]. 
Colonisation of dental plaque by respiratory pathogens is important in VAP 
aetiology, and it is also known that for the majority of critically ill patients, oral 
hygiene frequently deteriorates during mechanical ventilation [25,26]. 
Furthermore, not all oral hygiene interventions appear effective at reducing 
VAP incidence [27,28] and a recent meta-analysis even suggested that 
accepted oral hygiene treatments, such as use of chlorhexidine may actually 
lead to harmful effects [29]. 
In order to deliver effective oral care to critically ill patients to reduce VAP, it is 
important to increase our understanding of the dynamics of the oral 
microbiome during mechanical ventilation and how this relates to 
contamination of both the ETT and lower airway. The current study examined 
the nature of microbial changes in dental plaque and the lower airway, during 
mechanical ventilation and, in contrast to previous studies, during the patient 
recovery after mechanical ventilation.  
 
 
Materials and Methods 
Methods 
Patient recruitment  
Ethical approval was obtained from the National Research Ethics Service 
(NRES) within the Research Ethics Committee (REC) for Wales (Ref: 
13/WA/0039). In order for sufficient statistical power (>80%) to observe a 20% 
change in at least one phylum in microbial profiles and associated 
downstream high-throughput techniques [30], the minimum number of 
participants required for the study was 101. Mechanically ventilated patients 
were eligible for inclusion in the study if they were aged >18 years, had >8 
original teeth, their anticipated period of mechanical ventilation was >24h and 
their expected survival was >24 h. Informed consent for participation in the 
study was obtained from the next of kin and also taken from the patient if they 
recovered capacity.  
Within 6h of critical care admission, a critical care mouth plan was completed 
to determine the level and frequency of oral care required. Oral care included 
toothbrushing 4 times a day with sterile water, moistening of the oral cavity 
and lips. Antiseptic mouthwashes were not used. Additional care was 
provided for denture wearers. VAP was diagnosed using the existing Patients 
with a clinical suspicion of VAP had a Clinical Pulmonary Infection Score 
(CPIS) calculated using parameters of temperature, white blood cell count, 
PaO2/FIO2 ratio, the presence of tracheal secretions and changes on chest 
radiograph. Quantitative microbiological culture (>103CFU/ml) of the lower 
airways by (bronchoalveolar lavage (BAL)/non-directed bronchoalveolar 
lavage (NBL) was undertaken if the CPIS score was >6BAL was performed 
bronchoscopically by an attending clinician, whilst NBLs were undertaken by 
the bedside nurse inserting a suction catheter through the catheter mount into 
the lung parenchyma and flushing and withdrawing sterile saline  [32-36]. 
 
Decayed, missing and filled teeth (DMFT) score 
The DMFT score was recorded (by a dental professional). The DMFT score is 
a measurement of dental caries status and is therefore an indicator of prior 
longer-term oral hygiene levels [31]. Each incidence of a tooth recorded as 
decayed, missing or filled results in a score of 1 to generate a score of 0-28, 
with higher scores representing poor oral health. Final DMFT scores can 
therefore range between 0-28. DMFT scores, although not reflective of the 
remaining dentition, may indicate prior differences in oral hygiene 
maintenance within the patient cohort and therefore the level of risk for dental 
plaque changes. 
Dental plaque collection 
Subgingival and supragingival plaque was collected using paper points (QED 
size 40) and dental examination kits (Minerva Dental) [37]. Collection was 
performed on 3 occasions during the first week of admission to critical care 
and then weekly. The fist sample was collected within 24 h the start of 
mechanical ventilation. A total of 9 paper points, sampling 3 teeth per area 
(front, middle and back) were used per collection. In cases where the patient 
did not have sufficient teeth for the above protocol, plaque was taken from the 
closest areas. Plaque specimens were suspended in transport medium [38] 
and processed using microbial culture on the day of collection.  
 
Collection of subglottic aspirations, non-directed bronchoalveolar 
lavages (NBLs), bronchoalveolar lavages (BALs) and endotracheal tubes 
(ETTs) 
Subglottic secretions were collected through a subglottic port in the ETT using 
a syringe and transferred into sterile universals. Subglottic aspirates and 
NBLs were aseptically transferred into universal containers and endotracheal 
tubes were collected and placed in sterile bags when available for transport to 
the microbiology laboratory. 
 
Identification of respiratory pathogens  
Clinical specimens were processed within a Class II safety cabinet. Dental 
plaque was vortex-mixed and spread-plated on to appropriate selective agar 
media for detection of Staphylococcus aureus (MSB; Mannitol Salt Agar, 
MSA) and Pseudomonas aeruginosa (Pseudomonas agar base; Lab M), 
which are prevalent VAP pathogens [39-41]. Agar media were incubated at 
37°C under aerobic conditions for 5 days.  
NBLs and BALs were centrifuged for 3 min at 10,000g, and the pellet re-
suspended in 1 ml of PBS. A 50-µl volume was spread-plated on the previously 
described selective agar. Growth of P. aeruginosa and S. aureus was 
recorded, and colonies of presumptive respiratory pathogens identified by 
biochemical testing. Staphylococcus aureus colonies were sub-cultured on 
MSA agar for 18-24 h at 37°C and tested for catalase and coagulase activity 
[42]. Colonies of P. aeruginosa were sub-cultured on Pseudomonas agar for 
18-24 h at 37°C and tested for oxidase activity.  
Definitive identification of S. aureus and P. aeruginosa was by species-
specific PCR (Table 1) [43,44]. DNA extraction employed a commercially 
available DNA extraction kit (Qiagen). PCR was performed in a total reaction 
volume of 50 µl containing 2 µl of DNA template. Thermal cycling parameters 
for S. aureus detection were an initial 5 min at 94ºC, followed by 35 cycles of 
94ºC for 40 s, 50ºC for 40 s and 72ºC for 1 min, with a final elongation step of 
72ºC for 10 min. For P. aeruginosa PCR, there was an initial denaturation 
step of 95ºC followed by 35 cycles of 94ºC for 45 s, 58.4ºC for 45 s and 72ºC 
for 1 min ending with 5 min at 72ºC.  
Antimicrobial susceptibility profiling 
Staphylococcus aureus and P. aeruginosa were cultured on Mueller Hinton 
agar at 37°C for 18-24 h. A 0.5 McFarland standard (108 cells/ ml) was 
prepared to create an inoculum for antimicrobial sensitivity testing. A sterile 
swab was used to homogenously inoculate the 0.5 McFarland standard 
across the agar. Cefoxitin discs were used to identify MRSA, whilst sensitivity 
profiles of P. aeruginosa and S. aureus were tested against 6-12 
antimicrobials discs (selected based on previous administration to patients 
and according to frequent antibiotics used for these microorganisms). Agars 
were incubated for 18-24 h at 37°C and subsequent zones of inhibition (ZOI) 
measured and categorisation of isolate susceptibility (sensitive, resistant and 
intermediate resistant) was done according to British Society for Antimicrobial 
Chemotherapy (BSAC) guidelines. For analysis, the isolate antimicrobial 
sensitivities were grouped into clinical site origin.  
Imaging of endotracheal tube biofilms  
A 0.5-cm section of an ETT was placed in 2 ml of 10% (v/v) formalin for 24 h, 
processed in embedded wax and sectioned to 20 µm. Peptide nucleic acid 
probes (PNA; 100 µmol; Panagene; Table 2) were prepared in hybridisation 
solution (10% (w/v) dextran sulphate, 10 mM NaCl, 30% (w/v) formamide, 
0.1% (w/v) sodium pyrophosphate, 0.2% (w/v) polyvinylpyrolidone, 0.2% (w/v) 
ficol, 5 mM disodium EDTA, 50 mM Tris HCl and 0.2% Triton-X at pH 7.5) 
[45]. 
Processing involved enzymatic pre-treatment to promote access of the biofilm 
to PNA probe hybridisation. A 50-µl volume of lysostaphin was added to the 
section which was incubated at 20°C for 30 min. A 100-µl volume of lysozyme 
(10 mg/ml) was then added followed by incubation at 37°C for 30 min. A 100-
µl volume of PNA probe (300 nM for all probes with exception of the S. 
aureus-specific probe which was at 450 nM) was added and incubated at 
55°C for 90 min. Sections were flooded with 2 ml of wash solution (5 mM Tris, 
15 mM NaCl and 1% (v/v) Triton X-100 at pH 10) and incubated at 55°C for 
15 min [45] prior to mounting under coverslips with Vectashield™ 
(Vectorlabs). Controls devoid of probe were included. 
Sections were imaged using a Leica TCS SP2 AOBS spectral confocal 
microscope (Leica, Heidelberg, Germany) and appropriate excitation and 
emission settings for FITC (ex max 494nm; em max 518nm); Cy 3 (ex max 
550nm; em max 570nm) and Cy 5 (ex max 650nm; em max 670nm). 
Micrographs were presented as image overlays of confocal fluorescence 
(colour) superimposed upon Nomarski differential interference contrast 
(greyscale).  
Statistical analysis 
Where appropriate, statistical analysis (t test sampling) was performed using 
IBM SPSS v20. 
 
Results 
Patient recruitment and demographics 
A total of 1016 patients were screened over 14 months. Of these, 5 patients 
were <18 years, 20 patients had <8 teeth, 210 patients were anticipated to be 
mechanically ventilated for <24h, 439 patients were not mechanically 
ventilated and 232 patients could not be consented. A total of 107 patients (65 
male and 42 female; mean age 54) met the inclusion criteria and were 
recruited following receipt of informed consent. The median duration of 
mechanical ventilation was 7 days. 
 
The study was performed in a single adult critical care unit.  Patients were 
recruited with various health backgrounds for admission to critical care. 
Patient demographics and clinical measurements are presented in table 3.  
There was a lower mean age (39 y) for acute/ poly-trauma (n=12), compared 
to respiratory failure (n=30; mean age of 60 y). The mean age of patients 
admitted/receiving mechanical ventilation following an out of hospital cardiac 
arrest (OOHCA) was 60 y (n=11). A total of 77 (71%) of mechanically 
ventilated patients received at least one antibiotic, and just under half of 
patients (49%) received >2 different antibiotics during the course of 
mechanical ventilation. Over 30 antibiotics were administered to patients 
during the clinical study (table 3). Antifungals (including nystatin and 
fluconazole) were also administered to mechanically ventilated patients 
(n=12). Of 107 patients, DMFT indices were obtained for 97 and these scores 
increased with age; a score >10 was typically recorded for patients >40 years 
of age.  
 
Microbiological analysis during mechanical ventilation 
A total of 848 dental plaque samples were obtained from 107 mechanically 
ventilated patients.  Of these, 592 were collected during mechanical 
ventilation, with a mean number of plaque samples of 5 per patient. At least 
one dental plaque specimen was colonised with either S. aureus (43 patients) 
or P. aeruginosa (23 patients) during mechanical ventilation. Co-isolation of S. 
aureus and P. aeruginosa occurred for 10 patients. Of 43 patients who were 
culture positive for S. aureus during mechanical ventilation, 21 (48%) were 
culture negative for S. aureus at the time of intubation. A total of 23 patients 
were culture positive for P. aeruginosa during mechanical ventilation, with 18 
(78%) patients culture negative for this species at the time of intubation 
(Figure 1). The dental plaque of 35 patients out of 107 (33%) therefore 
exhibited a change in microbial composition to incorporate at least one of the 
targeted respiratory pathogens.  
Staphylococcus aureus was detected in the lower airways of 37 patients, and 
predominately occurred with concurrent dental plaque colonisation. The 
subglottic secretions of 14 patients and 4 patients contained S. aureus and P. 
aeruginosa, respectively. Co-colonisation of P. aeruginosa from both dental 
plaque and lower airway specimens was higher than for S. aureus. Twenty 
nine patients were culture positive for P. aeruginosa, and 23 of these were 
positive from dental plaque culture. ETT biofilm imaging using PNA-CLSM 
facilitated detection and spatial location of targeted species in the ETT biofilm 
(Figure 2).  
Forty-one patients were clinically diagnosed and treated for VAP during the 
study. This apparent high VAP rate can be related to the patient cohort as 
many had prolonged ventilation (13 ventilated between 5 – 7 d and 57 
ventilated >7 d). Of these patients, 18 had respiratory pathogens within dental 
plaque during mechanical ventilation, and 24 patients were colonised with the 
same respiratory pathogen within the dental plaque and the lower airways at 
any time point. In addition 9 patients clinically treated for VAP had respiratory 
pathogens in their dental plaque from the start and over the course of 
mechanical ventilation.  
 
 
Antimicrobial sensitivity of S. aureus and P. aeruginosa isolates 
The majority (>70%) of tested isolates from all sites were susceptible to the 
antibiotics tested. A total of 114 isolates of S. aureus (table 4) were recovered 
both during mechanical ventilation and into the recovery period. Where 
differences were observed in sensitivities, S. aureus isolates with antibiotic 
resistance profiles were most frequently isolated from subglottic secretions 
and tended to more frequently exhibit resistance to erythromycin, penicillin 
and cefepime. The majority of S. aureus were sensitive to cefoxitin and 
ceftazidime irrespective of origin. Of the 56 P. aeruginosa isolates, 35 were 
from dental plaque. Antimicrobial resistance patterns for all tested antibiotics 
ranges between 2% (ciprofloxacin) to 23% of strains (meropenem) (table 5). 
Although only 5 P. aeruginosa isolates were recovered from endotracheal 
tube sections and one of these exhibited the most resistant profile across all 
antibiotics tested. P. aeruginosa isolates exhibited the greatest sensitivity to 
Tobramycin with antibiotic susceptibilities ranging from 80% of isolates 
sensitive to all antimicrobials in the ETTs, to 97.1% in the dental plaque. 
 
Antimicrobial sensitivity patterns for recovered isolates of P. aeruginosa 
between dental plaque, the lower airways and endotracheal tube biofilms 
were largely similar for 7 out of 10 patients. Similarly, for recovered isolates of 
S. aureus between dental plaque, the lower airways and endotracheal tube 
biofilms, antimicrobial sensitivity patterns were related for 21 out of 30 
patients. (All individual isolate sensitivities are shown within the 
supplementary material). 
 
In the context of this study, an MDR pathogen was defined as a pathogen 
exhibiting a resistant profile (In terms of ZOI according to BSAC guidelines) to 
at least three antibiotics. A total of 3 patients were colonized with MDR P. 
aeruginosa and 21 patients were colonized with an MDR S. aureus (8 patients 
colonized with MRSA as detected by resistance to cefoxitin with a ZOI 
<20mm). 
Dental plaque analysis after endotracheal tube extubation 
A total of 256 dental plaque samples were collected during the recovery 
period with 88 collected within 1 week post-endotracheal tube extubation, 66 
during week 2 post-extubation, 43 collected 3 weeks post-extubation and a 
further 59 were collected >1 month post-extubation. For a total of 31 patients, 
dental plaque was not collected due to either patient withdrawal upon 
recovery, or death. Out of the 35 patients that exhibited microbial changes 
during mechanical ventilation, analysis of post-extubation dental plaque was 
completed for 27 patients.  
These analyses allowed an assessment of persistence of respiratory 
pathogens in patients’ dental plaque. In patients where dental plaque was 
colonised with S. aureus, 71% reverted back to a predominantly normal oral 
microbiota, devoid of S. aureus colonisation after extubation. Similarly for 
patients whose plaque was colonised by P. aeruginosa, 55% became culture 
negative for P. aeruginosa after extubation. A bar graph (Figure 1) compares 
the colonisation of respiratory pathogens during mechanical ventilation and 
the recovery period, highlighting reversed-microbial changes during the 
recovery period. Readmission rates to critical care were similar for patients 
exhibiting a reverse-microbial change (11.1%) and those patients harboring 
pathogens within their dental plaque during the recovery period (10%).  
Discussion 
VAP is an important hospital acquired infection in critically ill patients [4] and 
is associated with increased mortality, duration of stay and cost [46]. 
Prevention of VAP is vital, and an important facet in the development of 
appropriate preventative strategies is a better understanding of the aetiology 
and pathogenesis of VAP [47,48]. 
The microbiome of the oral cavity is both highly diverse and dynamic, 
primarily because of the wide range of microbial habitats that exist in the 
mouth and the fluctuations that can arise in these environments due to 
changes in diet, salivary flow and oral hygiene interventions [49-54]. 
Unsurprisingly, since the oral cavity is directly linked to the lower airways, 
associations between oral microbiology and respiratory infections are 
frequently made. In the case of VAP, it has been suggested that oral 
microorganisms could promote colonisation of dental plaque and 
endotracheal biofilms by potential respiratory pathogens, or may directly 
cause VAP themselves [55]. Carrilho-Neto et al, showed a reduction in oral 
hygiene for the majority of hospitalized patients, reporting a positive 
correlation between dental plaque index and gingival index [56]. Gingival 
inflammation caused by poor oral hygiene in intubated patients may also drive 
inflammation within the lungs [56-58]. The primary objective of this study was 
to determine the colonisation dynamics for key microbial species at defined 
sites in critically ill patients undergoing mechanical ventilation. Although 
previous studies have examined colonisation with potential respiratory 
pathogens following critical illness, this has only been over a short duration of 
ventilation following intubation.  
An important finding of this study was that the composition of dental plaque in 
a significant proportion (approximately one third) of mechanically ventilated 
patients altered with inclusion of the potential respiratory pathogens S. aureus 
and P. aeruginosa. Importantly, these bacterial species may exhibit resistance 
to antibiotics, and are causative agents in up to 50% of VAP cases [39-41]. 
The presence of these targeted microorganisms in the endotracheal tube was 
also evident using the culture independent tool of PNA-FISH coupled with 
CLSM. Aggregates of respiratory pathogens were clearly evident using this 
approach. The displacement of respiratory pathogens to the lower airway 
would deliver infectious agents already within a biofilm phenotype and are 
therefore more resistant to host defence mechanisms and administered 
antimicrobials. Although only a small proportion of S. aureus isolates were 
reported as MRSA, ~25% isolates recovered from dental plaque were 
resistant to at least one antibiotic tested in vitro (tables 4 and 5.) When 
assessing antimicrobial resistant levels between isolates recovered within the 
dental plaque and the lower airways, the highest levels of resistance were 
recovered from outside of the oral cavity. Resistance rates were highest for P. 
aeruginosa within the ETT biofilm, and for S. aureus within subglottic 
secretions (table 4).  This can imply higher rates of resistance within the 
airways, and if VAP were to develop in these patients then this could 
exacerbate the success of antimicrobial therapy. 
Importantly, in the majority of patients where microbial changes occurred in 
the dental plaque, a reversal occurred once the patient was extubated, and 
this was most readily evident with S. aureus colonisation. A higher proportion 
of patients colonised with P. aeruginosa retained the respiratory pathogen 
colonisation post extubation. Although most dental plaque communities 
reverted back to a phenotype without target respiratory pathogens within one 
week of extubation, the fact that some patients remained colonised with 
respiratory pathogens over a prolonged duration could represent a patient 
group at risk of subsequent hospital-acquired pneumonia.  
Although not regarded as a normal inhabitant of the oral cavity, S. aureus has 
been detected within the dental plaque of debilitated or elderly individuals  
[59]. An observational study of hospitalized patients by Sachdev et al, (62% 
were not ventilated), revealed colonization rates of S. aureus at ~14% [26]. In 
the current study, the high incidence (43 of 107 patients) of S. aureus in 
dental plaque was nevertheless surprising, particularly as half of these 
patients did not have S. aureus in their dental plaque at the time of intubation. 
Similarly, dental plaque also became colonised with P. aeruginosa during 
mechanical ventilation, albeit at a lower incidence. As dental plaque is easily 
sampled, and is a less invasive procedure than a NBL or BAL, isolation of 
potential respiratory pathogens in dental plaque of patients with suspected 
VAP may enable targeted antimicrobial therapy and should be evaluated in 
future studies. In 6 mechanically ventilated patients, although P. aeruginosa 
was isolated within the lower airways there was no confirmation of P. 
aeruginosa via microbial culture within their dental plaque. Perhaps further 
investigation coupled with high-throughput technologies could elucidate 
whether P. aeruginosa could be detected if present in a much lower 
abundance. Furthermore, there is the potential for dental plaque analysis in 
guiding empiric therapy, however false negatives when relating to the 
occurrence of respiratory pathogens in the lower airways can occur.  
One of the main limitations of the current study is that target pathogens were 
limited to S. aureus and P. aeruginosa by culture specific methods. Whilst 
additional respiratory pathogens were not assessed in this study, others have 
found that E. coli, Klebsiella species and Acinetobacter species may also 
colonise dental plaque and endotracheal tubes during mechanical ventilation 
[2].  Furthermore we have demonstrated considerable microbial diversity and 
colonisation of plaque with potentially pathogenic bacteria using non-culture 
techniques such as community profiling by high throughput sequencing [30]. 
The reason(s) why such microbial changes occur in dental plaque remain 
unclear, but are likely linked to local environmental changes in the mouth. 
These may include plaque accumulation and gingival inflammation from 
inadequate delivery of oral care during mechanical ventilation, perturbations 
of salivary composition and reduced salivary flow as a consequence of 
incomplete mouth closure, or following receipt of drugs [60].  
This is to our knowledge, the first study in critically ill mechanically ventilated 
patients that has sequentially assessed the dental microflora over a prolonged 
duration and shown a decrease in respiratory pathogen colonisation of dental 
plaque in some patients during recovery from critical illness. Once elucidated, 
the reasons why the dental plaque of some patients’ begins to revert back to a 
profile of microbes without respiratory pathogens (identified during mechanical 
ventilation), potentially offers new preventative strategies for VAP. Whether 
those patients who have persistent colonisation with respiratory pathogens 
despite recovery from critical illness are at increased risk of hospital acquired 
infection needs to be evaluated in larger adequately powered studies.  It was 
evident from this present study that microbial changes occur in the dental 
plaque of mechanically ventilated patients and these include colonisation by 
respiratory pathogens. The presence of respiratory pathogens in dental 
plaque is a risk factor for VAP. Emphasising the importance of maintaining 
oral hygiene during mechanical ventilation, may actually limit this reservoir of 
respiratory pathogens within the dental plaque of mechanically ventilated 
patients.  
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 Species Target 
Gene 
Primers Amplicon 
size 
Reference 
S aureus Vick vicK1: 5’-CTA ATA CTG AAA 
GTG AGA AAC GTA-3’ 
vicK2: 5’-TCC TGC ACA 
ATC GTA CTA AA-3’ 
289bp 32 
P. aeruginosa ecfX Ps.aeru_ECF1: 5’-ATG GAT 
GAG CGC TTC CGT G -3’ 
Ps.aeru_ECF2: 5’-TCA TCC 
TTC GCC TCC CTG -3’ 
528 bp 33 
Table 1 - PCR primers for identification of S. aureus and P. aeruginosa. 
 
 
 
Probe 
 
Nucleotide sequence 
(5’-3’) 
Fluorescent 
marker (N- 
terminal) 
final probe 
concentration 
(nM) 
Bacterial 
Universal 
CTGCCTCCCGTAGGA Cy3-00- 300 
Pseudomonas 
aeruginosa 
AACTTGCTGAACCAC FITC-00- 300 
Staphylococcus 
aureus 
GCTTCTCGTCCGTTC Cy5-00- 450 
Candida 
albicans 
ACAGCAGAAGCCGTG FITC-00- 300 
 
Table 2 - Species-specific PNA probes and associated fluorescent labels  
 
 Recruited patients Patient NO. Gender Age Admission details (reason for MV) DFMT Antibiotic use 
1 PN001 M 51 Respiratory failure 8 Clindomicin, Meropenem 
2 PN002 M 33 Stroke/brain injury/seizures 4  -  
3 PN003 M 31 Overdose/suicide attempt 9  Co-amoxiclav 
4 PN004 F 55 Stroke/brain injury/seizures 19 Cefuroxime 
5 PN005 M 62 Stroke/brain injury/seizures 21 Cefuxome (in theatre) 
6 PN006 F 34 Respiratory failure 0 Meropenem, Gentimicin, Co-tremoxyle  
7 PN007 F 54 Stroke/brain injury/seizures 11 Cefuroxime 
8 PN008 M 63 Respiratory failure 12 Clarthromycin, co-amoxiclav 
9 PN009 F 77 Other 23 Meropenem, Tazocin 
10 PN010 F 30 Stroke/brain injury/seizures  -  Trimethroprim 
11 PN011 F 73 Respiratory failure 16 Augmentin Tazocin, Clarithromycin 
12 PN012 M 68 Respiratory failure 13 Tazocin 
13 PN013 F 50 Stroke/brain injury/seizures 14 - 
14 PN014 M 44 Respiratory failure 11 Meropenem, Tazocin 
15 PN015 F 49 Stroke/brain injury/seizures 11 Cefuroxime 
16 PN016 M 28 Other 4 Clindomicin, Meropenem 
17 PN017 F 51 OOHCA 23 - 
18 PN018 M 39 Overdose/suicide attempt  -  - 
19 PN019 M 69 Poly-trauma  22 Teicopleinin, Cefuroxime, Tobramycin, Erythromycin 
20 PN020 F 29 Poly-trauma  3 Tazocin,  
21 PN021 F 18 Stroke/brain injury/seizures 0 Aciclovir  
22 PN022 M 72 OOHCA 12 Tazocin  
23 PN023 M 19 Stroke/brain injury/seizures 5 Tazocin, Clarithomycin 
24 PN024 M 40 Stroke/brain injury/seizures 14 - 
25 PN025 F 27 Stroke/brain injury/seizures 4 - 
26 PN026 F 63 General surgery - Stomach  -  Meropenem 
27 PN027 M 41 Stroke/brain injury/seizures 5 - 
28 PN028 F 55 Respiratory failure 15 - 
29 PN029 M 76 Respiratory failure 15 Co-amoxiclav, Tazocin 
30 PN030 F 58 Stroke/brain injury/seizures 19 Ciprofloxacin, Metronizadole, Gentamycin 
31 PN031 F 31 Other  -  Meropenem,  
32 PN032 M 67 Stroke/brain injury/seizures 11 Augmentin, Tazocin, Clarithromycin 
33 PN033 F 85 Respiratory failure 17 Amoxicillin, Co-amoxiclav, Clarithromycin, Tazocin 
34 PN034 M 57 Other 18 Cefuroxime, Metronidazole, Ciprofloxacin, Gentamycin 
35 PN035 M 58 OOHCA 19 Tazocin 
36 PN036 M 60 OOHCA  -  
37 PN037 M 37 Stroke/brain injury/seizures 15 Ceftrixone, Meropenem, Ciprofloxacin 
38 PN038 M 37 Stroke/brain injury/seizures 0 Meropenem, Ciprofloxacin, Ceftriaxome 
39 PN039 F 86 Respiratory failure 17 Co-amoxiclav, Tazocin, Clarithromycin 
40 PN040 F 60 Respiratory failure 21 - 
41 PN041 F 58 Respiratory failure 26 - 
42 PN042 M 74 Stroke/brain injury/seizures 15 - 
43 PN043 M 59 Stroke/brain injury/seizures 6 - 
44 PN045 F 22 Stroke/brain injury/seizures  -  Tazocin 
45 PN046 M 48 OOHCA 12 - 
46 PN047 M 53 Stroke/brain injury/seizures 12 - 
47 PN048 M 57 Stroke/brain injury/seizures 7 Cefuroxime 
48 PN049 F 75 General surgery - Stomach 16 Gentamycin, Tazocin 
49 PN050 M 39 Stroke/brain injury/seizures 11 - 
50 PN051 F 73 Stroke/brain injury/seizures 8 Cefalexin, Meropenem 
51 PN052 M 65 Other 16 - 
52 PN053 F 66 Respiratory failure 11    Vancomycin, Tazocin 
53 PN054 M 66 Other 13 
54 PN055 F 60 Other 8 Meropenem, Vancomycin 
55 PN056 F 49 Stroke/brain injury/seizures 17 - 
56 PN057 M 53 Respiratory failure 11 - 
57 PN058 F 38 Stroke/brain injury/seizures 6 Meropenem 
58 PN059 M 86 General surgery - Stomach 28 Tazocin 
59 PN060 M 39 Stroke/brain injury/seizures 9 Cefuroxime, Co-amoxicillin 
60 PN061 M 36 Poly-trauma  14 Tobramycin, Colomycin, Cefuroxime 
61 PN062 M 21 Poly-trauma  1 Tobramycin, SDD oral paste, Colomycin, Cefotaxime,  
62 PN063 M 58 Respiratory failure  -  Amikacin, Tazocin, Clarithromycin 
63 PN064 M 44 OOHCA 23 - 
64 PN065 F 42 General surgery - Stomach 13 Gentamycin, Augmentin, Metronidazole, Tazocin,   
65 PN066 F 73 Respiratory failure 0 Augmentin, Tazocin, Meropenem 
66 PN067 M 68 Respiratory failure 19 Meropenem 
67 PN068 M 52 OOHCA 8 - 
68 PN069 F 82 General surgery - Stomach 20 - 
69 PN070 M 18 Poly-trauma  2 Cefotaxime, (SDD regime Nystatin, Colomycin), Tobramycin 
70 PN071 M 26 Poly-trauma  7 Augmentin, SDD: Nystatin, Colomycin, Cefuitoxime 
71 PN072 M 67 Respiratory failure 10 Tazocin 
72 PN073 M 59 Other 19 - 
73 PN074 F 51 Stroke/brain injury/seizures 17 Rifampicin, Meropenem, Vancomycin 
74 PN075 M 75 Stroke/brain injury/seizures 20 Cefotaxime, Amoxicillin, Meropenem, Vancoymcin, Gentamycin 
75 PN076 M 49 Respiratory failure 16 Tazocin, Clarithromycin 
76 PN077 M 70 Stroke/brain injury/seizures 18 Cefuroxime 
77 PN078 M 75 Respiratory failure 24 cotrimazole cream, Meropenem, Vancomycin  
78 PN079 F 51 Respiratory failure  -  Tazocin, Trimethroprim 
79 PN080 F 71 Respiratory failure 6 Meropenem 
80 PN081 M 74 Other 18 Tazocin 
81 PN082 F 45 Stroke/brain injury/seizures 1 Gentamicin 
82 PN083 M 47 Respiratory failure 1 Augmentin, Clarithromycin 
83 PN084 M 58 Poly-trauma  17 Augmentin, SDD: Colomycin and Tobramycin, Teicoplanin 
84 PN085 F 75 Respiratory failure 14 Meropenem 
85 PN086 M 74 Stroke/brain injury/seizures 5 
86 PN087 M 80 OOHCA 11 
87 PN088 F 40 Dental/Oral cavity 22 Meropenem, Clindamycin, Metronidazole 
88 PN089 M 38 Poly-trauma  15 Co-amoxiclav, Tobramycin, (SDD: Colistin + Nystatin) 
89 PN090 M 66 Respiratory failure 17 Tazocin, Co-trimoxizole 
90 PN092 M 55 Stroke/brain injury/seizures 13 Tazocin 
91 PN093 F 42 Stroke/brain injury/seizures 7 Meropenem, Ceftriaxone, Rifampicin, Vancomycin 
92 PN094 M 60 Respiratory failure 13 Co-amoxiclav, Clarithromycin 
93 PN095 M 41 Stroke/brain injury/seizures 9 - 
94 PN096 F 27 Other 1 Amoxicillin, Ceftriaxone 
95 PN097 F 77 Poly-trauma  22 Colomycin, Tobramycin, Cefotaxime  
96 PN099 M 58 Other 9 Rifampicin, Isoniazid, Pyrazinamide, Ethambutol 
97 PN100 M 26 Overdose/suicide attempt 6 Clarythromcin, Cefotaxime 
98 PN101 M 29 Respiratory failure 25 Meropenem 
99 PN102 M 30 Respiratory failure 8 Co-amoxiclav, Clarithromycin, Co-trimoxazole 
100 PN103 F 80 Respiratory failure  -  Augmentin, Co-amoxiclav, Clarithryomcin 
101 PN104 M 56 OOHCA 18 - 
102 PN105 M 67 OOHCA 14 - 
103 PN106 F 60 Respiratory failure 19 Amoxicilin 
104 PN107 F 47 Stroke/brain injury/seizures 12 - 
105 PN108 M 74 OOHCA  -  - 
106 PN109 M Respiratory failure 7 Tazocin 
107 PN110 M 60 Other   Metronidazole, Cefotaxime 
 
Table 3 - Patient demographics: age, gender, DMFT scores, admission details (primary reason for mechanical ventilation) and 
antibiotic administration 
 
 
 114 Isolates of S. aureus  
  Cefepime  Cefoxitin Ceftazidime  
Fusidic 
Acid Gentamicin  Meropenem  
Sensitive % 65 88 88 89 82 86 
Intermediate % 20 0 2 4 13 6 
Resistant % 15 12 11 7 4 8 
 
Ciprofloxacin  Clindamycin Erythromycin  Penicillin Tobramycin  Vancomycin  
Sensitive % 86 61 62 55 79 88 
Intermediate % 4 27 16 31 15 1 
Resistant % 11 12 22 14 6 11 
 
Table 4 - Antimicrobial sensitivities for S. aureus isolates 
 
56 Isolates of P. aeruginosa 
  Ceftazidime Ciprofloxacin Gentamicin Meropenem Piperacillin Piperacillin-Tazobactam Tobramycin 
Resistant % 8.8 1.8 1.8 22.8 15.8 10.5 1.8 
Sensitive % 82.5 87.7 66.7 64.9 40.4 63.2 96.5 
Intermediate % 8.8 10.5 31.6 12.3 43.9 26.3 1.8 
 
Table 5 - Antimicrobial sensitivities for P. aeruginosa isolates 
 
  
Figure 1 - Microbial colonisation of respiratory pathogens during endotracheal 
intubation and analysis during the recovery period (up to 8 weeks post ETT-
extubation).  
 Figure 2 - Micrographs of endotracheal tube (ETT) biofilm obtained by 
confocal laser scanning microscopy (CLSM). All micrographs show a confocal 
fluorescence image superimposed (colour) upon a Nomarski differential 
interference (greyscale) A) Aggregates of bacteria hybridised with the 
universal bacterial Peptide Nucleic Acid (PNA) probe labeled with Cy-3 
(red); B) Pseudomonas aeruginosa hybridised with species specific FITC 
labelled PNA probe (green); C) Staphylococcus aureus hybridised with 
species specific PNA probe conjugated with Cy-5 (blue). Where possible, the 
edge of the ETT section is arrowed.  
 Patient Antibiotic 
Patient 
 
Sample Cefepime Cefoxitin Ceftazidime Ciprofloxacin Clindamycin Erythromycin 
Fusidic 
Acid Gentamicin Meropenem Penicillin Tobramycin Vancomycin  
  
PN004 SUB 25 0 20 35 0 0 0 26 26 0 22 0 
PN005 DP 28 29 16 28 0 0 30 24 34 16 22 16 
PN005 DP 27 29 19 28 0 0 36 24 38 17 23 16 
PN007 DP 27 30 20 20 27 26 30 22 34 40 22 17 
PN007 DP 28 29 18 21 36 25 36 22 36 16 22 16 
PN007 DP 24 28 18 21 22 26 31 24 32 29 21 16 
PN007 DP 27 0 28 35 0 0 24 23 35 0 22 0 
PN009 DP 24 29 18 27 20 24 33 23 36 42 20 18 
PN009 NBL 22 28 17 24 30 24 33 23 33 33 23 16 
PN009 DP 23 29 16 22 30 18 32 22 31 28 22 16 
PN015 DP 28 0 27 35 0 0 0 23 36 0 25 0 
PN021 ETT 26 31 14 21 29 21 35 24 36 17 21 16 
PN021 DP 27 29 17 20 30 24 36 23 39 16 19 16 
PN021 NBL 28 30 18 20 30 25 35 22 36 15 23 16 
PN021 DP 24 29 17 22 28 21 30 22 32 29 21 17 
PN024 SUB 26 30 19 21 28 26 30 23 31 15 21 16 
PN024 NBL 25 29 19 22 27 26 30 22 30 17 22 16 
PN024 ETT 24 29 18 22 27 23 29 23 33 30 22 18 
PN024 DP 23 30 19 26 30 23 31 22 30 39 20 18 
PN024 NBL 27 28 16 28 29 22 32 23 33 36 21 19 
PN025 DP 25 30 17 27 28 24 30 23 32 30 21 16 
PN025 NBL 27 30 18 28 30 24 31 22 31 34 22 17 
PN025 NBL 27 29 17 27 28 25 30 22 30 40 22 16 
PN025 ETT 26 29 18 26 27 25 32 23 32 29 21 18 
PN027 NBL 28 29 28 34 29 23 30 24 31 40 21 17 
PN027 NBL 25 29 16 0 29 24 30 22 30 30 23 17 
PN027 ETT 23 30 18 0 22 0 30 22 10 0 21 17 
PN028 ETT 0 9 0 24 23 0 30 25 0 0 19 14 
PN028 SUB 0 10 0 12 29 0 33 22 13 7 22 16 
PN028 NBL 0 11 0 0 31 0 30 22 12 0 22 17 
PN037 DP 24 30 18 26 28 18 31 25 30 17 20 18 
PN037 NBL 25 30 19 27 24 27 30 23 30 17 21 17 
PN037 NBL 31 30 20 25 28 26 30 24 30 19 19 18 
PN037 NBL 24 30 17 24 28 22 30 24 30 20 20 20 
PN042 DP 24 30 18 24 28 23 30 24 30 20 20 20 
PN042 NBL 24 30 18 25 24 23 30 24 30 20 19 18 
PN042 SUB 16 0 0 25 13 26 30 24 18 0 14 15 
PN042 ETT 24 30 18 25 28 22 30 22 30 30 19 19 
PN043 DP 24 30 18 24 28 22 30 24 30 18 18 18 
PN045 DP 22 29 19 23 30 23 30 22 32 21 22 19 
PN046 DP 24 30 18 25 28 22 30 22 30 28 19 19 
PN046 NBL 24 30 18 25 28 22 30 22 30 28 19 19 
PN046 DP 25 30 19 24 28 22 30 22 30 28 18 14 
PN046 NBL 27 30 20 27 25 19 29 22 29 21 22 18 
PN046 ETT 24 30 18 24 28 22 28 23 30 28 18 21 
PN046 DP 22 30 20 23 30 22 29 0 31 18 20 18 
PN048 NBL 25 30 18 24 24 18 30 22 30 28 20 20 
PN049 DP 22 30 19 25 21 20 30 19 29 19 22 20 
PN049 NBL 20 30 20 24 21 23 29 25 32 29 24 0 
PN049 DP 25 0 18 11 10 22 19 20 30 20 14 0 
PN050 DP 22 30 19 25 28 20 30 22 30 28 19 20 
PN050 NBL 22 29 20 24 28 19 29 19 30 19 20 20 
PN050 ETT 23 30 20 22 29 19 29 23 30 28 20 20 
PN051 DP 23 30 19 0 28 0 29 19 30 28 24 20 
PN051 DP 20 30 20 22 21 19 30 22 29 22 24 21 
PN052 DP 24 31 18 24 0 0 29 22 30 28 22 19 
PN052 NBL 23 30 19 24 30 23 29 22 30 29 21 4 
PN052 ETT 21 30 19 22 21 22 29 22 30 20 20 11 
PN054 NBL 23 30 20 24 22 23 30 22 30 21 19 19 
PN056 DP 23 30 20 22 29 19 29 22 30 19 22 19 
PN056 NBL 23 30 20 22 29 19 30 24 30 29 19 21 
PN056 DP 19 29 21 22 22 23 30 18 30 29 21 19 
PN056 NBL 20 30 19 22 29 23 30 24 29 28 21 19 
PN056 SUB 19 30 21 22 21 23 30 18 30 28 22 20 
PN056 SUB 19 30 21 23 21 22 30 18 28 21 21 21 
PN057 NBL 19 29 20 23 22 22 30 22 30 19 21 22 
PN057 ETT 20 30 18 23 22 19 29 23 30 21 21 21 
PN058 SUB 19 29 20 21 22 22 29 18 30 30 22 0 
PN063 NBL 20 29 18 22 22 19 29 18 30 30 22 0 
PN068 DP 21 30 20 0 9 0 30 20 30 30 20 0 
PN068 NBL 22 30 20 22 28 0 26 21 29 28 0 28 
PN068 DP 22 30 19 21 28 28 11 21 30 29 21 19 
PN077 NBL 22 29 19 21 27 22 29 20 21 22 19 19 
PN077 DP 22 30 19 26 28 22 30 20 32 23 20 0 
PN077 NBL 21 30 20 22 28 22 30 20 30 29 21 19 
PN080 SUB 0 14 0 10 28 0 30 10 20 0 10 21 
PN080 DP 0 13 0 0 32 0 30 10 21 0 10 21 
PN080 DP 0 15 0 0 33 0 33 11 21 0 0 21 
PN081 NBL 0 0 0 0 28 23 10 27 30 0 20 0 
PN081 SUB 0 0 0 0 32 26 29 23 7 0 20 9 
PN081 DP 0 9 0 0 33 29 31 24 14 0 23 18 
PN081 DP 0 8 0 0 30 27 21 24 9 0 22 17 
PN086 NBL 23 30 19 23 28 22 29 22 29 21 22 20 
PN087 ETT 21 30 19 23 28 19 30 24 29 21 24 20 
PN087 NBL 25 20 16 21 29 8 29 22 29 17 23 20 
PN087 SUB 24 30 19 24 22 0 30 22 30 28 22 20 
PN087 DP 23 30 20 22 28 0 30 22 29 29 21 20 
PN089 NBL 23 30 20 24 28 22 30 24 30 29 21 19 
PN089 SUB 23 29 21 22 21 22 29 22 30 28 20 21 
PN089 NBL 25 30 22 23 28 24 29 23 29 31 20 20 
PN089 DP 21 30 21 24 28 22 29 23 29 28 21 19 
PN092 DP 23 30 22 0 21 23 30 22 27 24 21 20 
PN092 NBL 21 30 20 23 21 24 29 23 29 29 22 20 
PN094 NBL 24 29 21 22 28 23 30 22 29 29 21 19 
PN095 DP 21 29 21 22 0 0 29 22 29 32 21 20 
PN095 NBL 29 32 17 22 0 0 17 25 35 29 22 19 
PN095 SUB 26 30 14 24 0 0 19 24 33 29 18 18 
PN095 DP 22 30 18 24 0 0 19 23 29 18 21 0 
PN097 NBL 23 30 21 24 24 23 30 21 31 31 22 18 
PN099 DP 20 29 23 24 28 22 30 23 30 28 21 21 
PN099 DP 23 30 19 22 27 19 29 23 30 29 21 18 
PN102 DP 23 30 19 23 25 22 29 22 33 29 19 19 
PN102 DP 20 29 22 21 0 0 30 22 34 30 21 20 
PN104 DP 21 30 24 23 28 24 30 24 30 21 21 17 
PN104 NBL 21 30 21 23 21 25 30 24 30 29 22 18 
PN104 DP 20 30 22 24 21 23 30 23 30 28 20 21 
PN105 NBL 20 30 21 20 28 23 30 23 30 31 22 19 
PN105 ETT 24 30 22 21 21 24 30 23 29 29 20 18 
PN106 ETT 22 30 23 21 28 23 29 23 30 30 21 19 
PN108 DP 20 30 22 23 21 23 30 23 30 28 19 20 
PN108 NBL 24 30 19 23 28 22 29 22 29 28 21 20 
PN108 ETT 21 30 16 23 29 22 31 24 30 28 20 19 
PN109 DP 20 30 17 24 24 22 32 22 32 30 20 17 
PN110 NBL 0 0 0 10 32 0 25 12 0 0 12 20 
Resistant   
Supplementary table 1 – Individual antimicrobial sensitivities for S. aureus isolates obtained during mechanical, and where 
possible, into the post- endotracheal tube extubation recovery period.  
 
Patient Antibiotics 
Patient  Sample Ceftazidime Ciprofloxacin Gentamicin Meropenem Piperacillin Piperacillin-Tazobactam Tobramycin 
PN006 DP 22 30 20 27 24 27 19 
PN007 DP 22 30 20 28 24 27 22 
PN008 DP 24 30 26 28 24 27 21 
PN018 DP 22 30 19 27 24 28 21 
PN018 NBL 23 30 18 32 25 27 20 
PN030 DP 19 30 19 28 23 27 20 
PN030 NBL 20 30 19 29 24 27 20 
PN030 SUB 21 29 20 30 24 27 19 
PN030 NBL 22 29 20 30 24 29 19 
PN030 ETT 23 30 18 32 20 26 20 
PN030 DP 19 31 19 31 18 26 20 
PN038 DP 22 30 24 0 18 20 20 
PN045 NBL 22 30 22 0 17 21 22 
PN047 DP 22 29 19 20 21 26 24 
PN047 DP 19 28 21 27 22 29 22 
PN047 DP 22 30 19 27 23 26 19 
PN047 DP 21 30 20 27 19 27 20 
PN048 NBL 22 30 20 28 23 27 21 
PN049 DP 21 30 19 28 17 18 19 
PN049 DP 22 30 18 18 23 26 21 
PN051 DP 21 30 20 27 23 28 21 
PN060 DP 23 30 21 27 21 25 22 
PN060 DP 22 30 21 18 14 19 21 
PN060 DP 21 30 19 29 21 28 19 
PN062 DP 22 31 21 29 22 27 19 
PN062 NBL 22 28 21 28 22 27 19 
PN062 DP 22 30 20 0 23 25 20 
PN075 DP 20 30 20 29 21 26 19 
PN078 NBL 21 30 20 28 20 28 20 
PN079 SUB 22 30 18 30 21 26 20 
PN079 DP 22 30 21 28 0 14 19 
PN079 NBL 23 30 21 29 19 28 22 
PN079 DP 22 27 19 6 11 15 21 
PN079 DP 22 27 19 0 12 17 21 
PN081 DP 23 30 20 0 21 26 20 
PN083 NBL 23 30 21 10 19 27 21 
PN095 SUB 22 29 20 29 20 29 19 
PN095 DP 20 29 21 29 21 28 22 
PN095 ETT 22 29 21 29 19 29 19 
PN095 DP 22 30 21 0 18 29 18 
PN095 NBL 21 30 18 10 22 29 19 
PN095 SUB 21 30 23 28 23 27 20 
PN102 DP 21 30 20 30 24 28 20 
PN104 DP 20 30 19 30 21 28 20 
PN105 ETT 24 30 19 28 24 27 21 
PN105 NBL 25 30 19 29 24 29 21 
PN105 DP 21 29 21 29 21 28 21 
PN106 DP 19 29 21 27 23 27 19 
PN107 DP 22 30 21 30 22 28 20 
PN108 ETT 16 7 17 19 11 19 14 
PN109 DP 20 30 21 31 23 28 20 
PN109 DP 23 30 21 27 23 29 20 
PN109 DP 22 29 21 29 25 28 19 
PN110 DP 22 28 20 28 21 25 20 
PN110 NBL 23 27 21 28 22 26 19 
PN110 ETT 22 30 21 29 22 26 21 
Resistant   
Supplementary table 2 - Individual antimicrobial sensitivities for P. aeruginosa isolates obtained during mechanical, and where 
possible, into the post- endotracheal tube extubation recovery period. 
